The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target

The limitation of targeting VEGF/VEGFR2 signalling to stop angiogenesis in cancer therapy has been blamed on re-activation of alternative receptor tyrosine kinases by compensatory angiogenic factors. Targeting MAPK and PI3K signaling pathways in endothelial cells may be an alternative or complementa...

Descripción completa

Detalles Bibliográficos
Autores principales: Meta, Elda, Imhof, Beat A., Ropraz, Patricia, Fish, Richard J., Brullo, Chiara, Bruno, Olga, Sidibé, Adama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746136/
https://www.ncbi.nlm.nih.gov/pubmed/29296234
http://dx.doi.org/10.18632/oncotarget.22598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746136/
https://www.ncbi.nlm.nih.gov/pubmed/29296234
http://dx.doi.org/10.18632/oncotarget.22598

Ejemplares similares